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Abstract
Background: Expedited partner therapy (EPT) has been shown to prevent reinfection in persons 
with gonorrhea and to plausibly reduce incidence. The Centers for Disease Control and Prevention 
recommends EPT as an option for treating sex partners of heterosexual patients. Few studies that 
examine how the reported use of this valuable intervention differs by patient and provider 
characteristics and by geography across multiple jurisdictions in the United States are currently 
available.
Methods: Case and patient interview data were obtained for a random sample of reported cases 
from 7 geographically disparate US jurisdictions participating in the Sexually Transmitted Disease 
(STD) Surveillance Network. These data were weighted to be representative of all reported 
gonorrhea cases in the 7 study sites. Patient receipt of EPT was estimated, and multivariate models 
were constructed separately to examine factors associated with receipt of EPT for heterosexuals 
and for men who have sex with men.
Results: Overall, 5.4% of patients diagnosed and reported as having gonorrhea reported 
receiving EPT to treat their sex partners. Heterosexual patients were more likely to have received 
EPT than men who have sex with men at 6.6% and 2.6% of patients, respectively. Receipt of EPT 
did not vary significantly by race, Hispanic ethnicity, or age for either group, although significant 
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variation was observed in different provider settings, with patients from family planning/
reproductive health and STD clinic settings more likely to report receiving EPT. Jurisdiction 
variations were also observed with heterosexual patients in Washington State most likely (35.5%), 
and those in New York City, Connecticut, and Philadelphia least likely to report receiving EPT 
(<2%).
Conclusions: With the exception of one jurisdiction in the STD Surveillance Network actively 
promoting EPT use, patient-reported receipt of the intervention remains suboptimal across the 
network. Additional efforts to promote EPT, especially for patients diagnosed in private provider 
and hospital settings, are needed to realize the full potential of this valuable gonorrhea control 
intervention.
BACKGROUND
Expedited partner therapy (EPT) is the practice of treating the sex partners of persons with 
curable sexually transmitted diseases (STD) without requiring their prior medical evaluation. 
In most instances, this involves giving patients medication or a prescription for medication 
to give to their sex partners; this is referred to as patient-delivered partner therapy. 
Randomized controlled trials conducted in the 1990s and in the last decade have established 
that EPT increases partner treatment and decreases patients’ risk of recurrent gonorrhea or 
chlamydial infection.1–3 This effect is particularly strong for gonorrhea, with EPT resulting 
in a 9% or greater absolute reduction in gonorrhea risk in the months after treatment.3 More 
recently, investigators in Washington State reported that making patient-delivered partner 
therapy widely available at no cost to medical providers led to broad use of the intervention 
and seemed to decrease the rate of gonorrhea and chlamydia test positivity at the population-
level in women.4
Centers for Disease Control and Prevention (CDC) STD treatment guidelines recommend 
that clinicians use EPT for treating sex partners of heterosexuals with uncomplicated 
gonorrhea. However, how often patients actually receive EPT has not been well described. 
At least half of US medical providers report using EPT at least sometimes, with 15% to 50% 
reporting that they do so routinely.5–7 Although several studies have looked at EPT in single 
clinical sites,8–10 data on EPT use in networks of clinics and population-based studies are 
extremely limited and do not provide a useful estimate of overall EPT use in the United 
States.11
We used data collected through the CDC’s STD Surveillance Network (SSuN) to evaluate 
how often patients with gonorrhea report receiving EPT for their partners. A previously 
published study using SSuN data demonstrated a relationship between EPT and the legal and 
regulatory environment in SSuN jurisdictions.12 The previous SSuN analysis was limited to 
data collected in 2010; we include 2 additional years of data in the current study with the 
broader goal of describing patient and provider differences in self-reported receipt of EPT 
among persons reported with gonorrhea.
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METHODS
SSuN and Participating Sites
SSuN CYCLE 2 is a CDC-funded cooperative agreement supporting 12 city and/or state 
health departments to collect sentinel surveillance data related to cases of gonorrhea 
diagnosed and reported in their jurisdictions and on all patients seeking care in sentinel 
clinical facilities.13 This network is designed to collect more detailed epidemiologic and 
health services data than is available through routine public health case reporting with the 
goal of informing national prevention and care programs.14 Participating health departments 
randomly select a sample of reported gonorrhea cases and attempt to interview those cases 
using consensus protocols. Sites are required to contribute a minimum of 240 completed 
case interviews among the randomly selected cases annually to the national data set, 
although most sites contribute considerably more and are encouraged to set sample fractions 
reflecting their local capacity to recruit patients and conduct interviews. Participating sites 
transmit basic, de-identified data on all cases, as well as interview data for those in the 
random sample to CDC quarterly. The minimum number of interviews required reflects the 
variation in incidence across sites and overall funding available for the cooperative 
agreement.
Although 12 sites participated in SSuN cycle 2, the proportion of all reported cases that were 
randomly sampled varied from 4% to 97%, and local success in interviewing sampled cases 
varied substantially from 24.1% to 78.4%. To minimize potential response bias, we 
restricted our analyses to SSuN sites with interview completion rates of 40% or greater 
(Baltimore, California [excluding San Francisco], Colorado, Connecticut, New York City, 
Philadelphia, and Washington State).
The SSuN is a sentinel disease surveillance activity and as such did not require human 
subjects review by CDC. Collection of data from SSuN sites was conducted with Office of 
Management and Budget approval (Office of Management and Budget Number 0920–0842). 
No personally identifiable information was available to CDC or the analysts, or was used in 
any way for these analyses.
Description of Data
A random sample of gonorrhea cases reported between January 1, 2010, and December 31, 
2012, were identified by local project staff and referred for interview. We defined patients 
eligible for receipt of EPT as those who reported 1 or more sex partners in the 60- to 90-day 
period before their gonorrhea diagnosis and who did not report seeking medical care 
specifically because of contact with just a single sex partner diagnosed and previously 
treated for any STD. Clinicians and public health staff would have no basis to offer EPT to 
patients reporting only a single previously treated partner.
In most jurisdictions, patients were asked questions specifically designed to determine 
whether the responding patient was given medications or prescriptions by their provider or 
local health department personnel for their most recent sex partner (e.g., “Were you given 
medication or a prescription to give to your partner/s?”). In Washington State, interviewers 
asked respondents about each of their sex partners in the prior 60 days, whether their 
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partners were already treated at the time of the interview, and, if so, how their partners were 
treated. Responses to this question included “original patient gave meds to this partner” and 
“original patient gave prescription to partner.” Persons who reported receiving medications 
or a prescription to give to a partner were defined as having received EPT. Information on 
the most recent sex partner is included in SSuN data sets.
We evaluated receipt of EPT among heterosexuals and men who have sex with men (MSM) 
separately because of ongoing concerns with the routine use of EPT for treating partners of 
persons with gonorrhea in gay, bisexual, and other MSM, including a lack of evidence 
supporting the efficacy of EPT among MSM, as well as the potential loss of opportunities to 
test these patients for other STDs, such as syphilis or HIV.15 We defined MSM as men who, 
at the time of their SSuN interview, reported that they had any male sex partners in the 60 to 
90 days before their STD diagnosis regardless of whether they also reported female partners. 
We defined the heterosexual population to include men not reporting any male sex partners 
and all female patients reporting male sex partners.
Data Analyses
Individual case weights were calculated to adjust for the site specific sample fractions, 
which varied from 10.3% to 25.8% of all reported cases, and for nonresponse based on the 
distribution of patient sex, age group, and diagnosing provider type (e.g., family planning 
clinic, STD clinic, etc) in the population of all reported cases. Analyses of weighted data 
allowed us to estimate the number and proportion of patients diagnosed and reported in each 
study site who were eligible for EPT and received EPT. We report standard Wald 95% 
confidence intervals (CIs) for estimated EPT use.
Covariates available in the SSuN data included MSM status, age group, race/Hispanic 
ethnicity, and category of diagnosing provider. Adjusted odds ratios (AORs) and 95% CIs 
for differences by these covariates were obtained by logistic regression using a generalized 
logit function and Taylor series variance estimates with a finite population correction. We 
selected reference categories either in the middle, or at the extremes, of observed 
distributions for contrast purposes. All analyses were performed using SAS 9.3 (SAS 
Institute, Carey, NC).
RESULTS
A total of 170,063 cases of gonorrhea were reported in the 7 selected SSuN sites during the 
study period, of which 23,363 (13.7%) were randomly selected for interview (Table 1). The 
sample fraction in sites meeting the thresholds for inclusion in the analysis varied between 
10.3% and 25.8% of all cases reported. Project staff in these sites interviewed a total of 
10,988 cases for a response rate of 47% of the overall random sample. Interview response 
rates varied across jurisdictions from 40.2% to 78.3%. Based on weighted analyses, we 
estimated that 92.3% of all persons reported with gonorrhea met our criteria as eligible to 
receive EPT (95% CI, 91.2%–93.4%). Among all eligible patients, 5.4% reported receiving 
EPT (95% CI, 4.6%–6.2%). We found that receipt of EPT varied significantly between 
MSM and heterosexual patients, between sites, and by provider setting.
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Men who have sex with men comprised an estimated 27.9% (95% CI, 26.1%–29.8%) of all 
reported cases. Among these, 96.1% were estimated to be eligible for EPT at the time of 
their diagnosis (95% CI, 94.1%–98.2%). The overall percentage of MSM patients estimated 
to have received EPT was 2.6% (95% CI, 1.7%–3.4%). This percentage varied by site from 
less than 1% in New York City to 13.2% in Baltimore (Table 2). In a multivariate model of 
MSM patients controlling for age group, race/ethnicity, provider setting, and SSuN site, 
significant variation in receipt of EPT was observed by SSuN site and by diagnosing 
provider setting. Men who have sex with men reported in Baltimore (AOR, 7.29; 95% CI, 
1.62–32.78) and Washington State (AOR, 6.73; 95% CI, 2.38–19.10) were significantly 
more likely to report receiving EPT, and those diagnosed in New York City (AOR, 0.04; 
95% CI, 0.0–0.35) were less likely to report receiving EPT compared with MSM diagnosed 
in the reference site (Colorado). Men who have sex with men who received their diagnosis in 
family planning/reproductive health settings (AOR, 2.54; 95% CI, 1.03–6.26) and in other/
unknown settings (AOR, 2.21; 95% CI, 1.00–4.87) were more likely to report receiving EPT 
compared with MSM reported from STD clinics.
Among heterosexual men and women, 90.8% (95% CI, 89.6%–92.1%) were eligible to 
receive EPT. Overall among these patients, 6.6% (95% CI, 5.5%–7.7%) reported receiving 
EPT. The proportion of eligible heterosexual patients with gonorrhea reporting receiving 
EPT varied by jurisdiction (Table 3) from less than 1% in New York City to more than 35% 
in Washington State. Similarly, multivariate models exploring EPT use among heterosexuals 
while controlling for SSuN site, sex, age group, race/Hispanic ethnicity, and provider setting 
were constructed. Receipt of EPT was found to be significantly associated with SSuN site, 
patient sex, and provider setting. Eligible heterosexual patients in Washington State were 
much more likely to report receiving EPT than patients in Colorado, the reference site 
(AOR, 6.66; 95% CI, 4.03–10.99). Heterosexual men were less likely than women to report 
receiving EPT (AOR, 0.67; 95% CI, 0.47–0.95), and patients diagnosed in hospital or 
emergency departments (EDs), private provider settings, and other/unknown settings were 
less likely to report receiving EPT than those diagnosed in STD clinics.
DISCUSSION
Overall, we found that 5.4% of all patients diagnosed as having gonorrhea in SSuN 
jurisdictions reported receiving EPT from their provider or from the health department to 
treat their sex partners. Receipt of EPT varied significantly by sex of sex partners, with 
heterosexual patients reporting receipt of EPT more frequently than MSM (6.6% vs. 2.6%, 
respectively). Reported receipt of EPT also varied significantly by SSuN jurisdiction, 
regardless of MSM status.
A prior study of reported receipt of EPT in SSuN from 2010 found that 9.5% of patients 
with gonorrhea reported receiving EPT and demonstrated that permissive laws and favorable 
regulatory environments were associated with higher levels of EPT use.12 Our analysis 
differs in several important respects from the previous study in that we include 2 additional 
years of data and exclude several jurisdictions with low interview response rates and/or 
sample fractions. In addition, we assessed receipt of EPT in MSM and among heterosexuals 
separately, with the goal of specifically identifying differences by patient characteristics, 
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regardless of the legal or regulatory environment. The criteria we used to determine which 
patients could be considered eligible for EPT also differed. More patients were considered 
eligible for EPT and included in our denominators for the current analysis. In light of the 
often considerable time that elapses between patients’ initial gonorrhea diagnosis and their 
interview by SSuN investigators, a significant proportion of patients who reported in these 
interviews that their partners were treated may have had untreated partners at the time of 
their initial diagnosis; we considered these patients eligible to receive EPT. For these 
reasons, the more modest proportion of patients we observe reporting receipt of EPT in the 
current analysis may be more representative of patients receiving EPT across the full range 
of community settings in SSuN sites.
Among heterosexual gonorrhea cases reported in SSuN sites, we found that our estimates 
varied significantly, with roughly half of the sites reporting very few patients receiving EPT 
(<2%), half reporting modest levels (7%–10%), and one site reporting that more than one-
third of heterosexual cases report being given EPT for their partners. We expected receipt of 
EPT to be lower among MSM patients than among heterosexuals because of the lack of a 
CDC recommendation for providing EPT to MSM with gonorrhea. Not surprisingly, we 
observed reported receipt of EPT among MSM to be fairly low overall, although there was 
variability across SSuN sites suggesting that local practices may differ somewhat. Baltimore 
City was conducting a pilot project implementing EPT for use exclusively among 
heterosexuals during the study period. However, this site also had the highest estimated 
receipt of EPT among MSM. Investigators in Baltimore report (personal communication) 
that a high proportion of local MSM patients also had female sex partners; these patients 
may not have disclosed their history of male sex partners to the provider at their initial 
diagnosis, would not have been considered MSM, and would have been provided EPT as per 
local recommendations for heterosexuals.
Reported receipt of EPT did not vary significantly by age group or by race and Hispanic 
ethnicity for MSM, and only marginal variation was observed among heterosexuals by these 
categories. This finding is promising, given inequalities historically observed in gonorrhea 
case incidence,16 with younger age groups and non-Hispanic black populations bearing a 
disproportionate burden of disease. Any bias in receipt of EPT by patient demographic 
characteristics could have a differential impact on reinfection rates, potentially exacerbating 
existing inequities.
We also observed differences in patient-reported receipt of EPT by provider setting for both 
MSM and heterosexuals. Among both heterosexuals and MSM, patients reported from 
family planning/reproductive health clinics were significantly more likely to report receiving 
EPT. We also found that a lower proportion of heterosexual patients diagnosed in private 
providers and hospital/EDs and from unknown provider settings reported receiving EPT 
compared with patients diagnosed in STD clinics. Although systematically exploring the 
reasons for variations in EPT receipt across the spectrum of diagnosing providers was 
beyond the scope of our study, there may be plausible explanations for the higher proportion 
of patients we observed reporting receipt of EPT in family planning and STD clinic settings.
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Family planning settings typically serve young women (and often their male partners) 
seeking reproductive health services. Clinicians in these settings may be more aware of the 
importance of assuring partner treatment to prevent reinfection because of their continuing 
engagement with their patients and may be more aware of EPT as an option for the 
management of STDs. Similarly, clinicians providing care in STD clinics, which are 
predominantly publically funded, could also be expected to be familiar with current CDC 
treatment guidance and partner services recommendations. Provision of EPT to patients in 
STD clinic settings may be somewhat less frequent than in family planning settings, which 
is consistent with our findings because clinicians practicing in STD clinics may be more 
aware of concerns with providing EPT to their MSM patients. They likely serve a higher-risk 
heterosexual patient population as well; higher-risk patients may not be considered suitable 
candidates for EPT by their providers because of the patient’s real or perceived inability or 
unwillingness to contact recent sex partners.
Our analysis also highlights the extent to which receipt of EPT varies across jurisdictions in 
the SSuN. Some of this variation is due to local differences in the legal and regulatory status 
of EPT. Although EPT was permissible in some form in all SSuN sites included in our study 
as of December 2012, a statute explicitly enabling EPT did not become effective until 
October 2011 in Connecticut, and in New York, EPT is expressly authorized only for 
chlamydial infection.17 This likely explains the lower proportion of patients reporting receipt 
of EPT in these sites. Receipt of EPT was also observed to be demonstrably higher in 
Washington State, where specific programmatic efforts to promote EPT were undertaken.
Investigators in King County, Washington, developed a model for population-based EPT 
promotion in the late 1990s, which was subsequently implemented throughout Washington 
State as part of a community-level randomized trial.4,18 An important component of the 
intervention in Washington State was the provision of free EPT medications to index 
patients through partner packs or prescriptions that could be filled at no cost through 
participating pharmacies. At the conclusion of their trial, the investigators reported that the 
proportion of heterosexual patients provided EPT by medical providers was 34%.4 Our 
estimate of the proportion of patients receiving EPT among heterosexuals in Washington 
State for 2010 to 2012 is similar to those findings, reflecting sustained levels of EPT use 
beyond their community trial period.
Our findings are subject to several important limitations. It is important to note that our data 
can only measure whether a patient reported receiving EPT from a provider, not whether the 
patient actually gave EPT to his/her sex partners. The STD Surveillance Network includes 
geographically diverse populations covering approximately 20% of the US population; 
however, results are not necessarily generalizable to those states or jurisdictions not 
participating in SSuN. Interview response rates varied between study sites, raising concerns 
about potential nonresponse bias. We calculated poststratification weights to adjust for 
differences in response by sex, age, and diagnosing provider setting, but unmeasured biases 
may remain. One SSuN site (Washington State) collected information on EPT from 
interviewer-documented partner management outcomes, rather than patient self-report in a 
single question. This method is arguably more sensitive for capturing all partner services 
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information, yet probably does not account for the large difference in EPT use observed 
between Washington State and other SSuN jurisdictions.
In conclusion, we estimate that 6.6% of heterosexuals and 2.6% of MSM with gonorrhea in 
7 sites participating in SSuN received EPT from a provider or health department. This 
estimate varied between sites from less than 1% of patients in New York City to more than a 
third of eligible heterosexual patients in Washington State. Although receipt of EPT was 
higher among women, among heterosexuals overall, and in some treatment settings, receipt 
of EPT remains suboptimal in many settings. Our findings highlight the need for additional 
efforts to promote the intervention. Cost and reimbursement issues may be among the more 
problematic impediments to the expanded use of EPT. It is unlikely that state or local STD 
programs can absorb the cost and administrative burdens of implementing statewide, 
population-based EPT initiatives, as seen in the Washington State EPT trial.
However, some components of the Washington State intervention model, such as enhancing 
provider awareness, triaging through case-reporting mechanisms, or provision of EPT 
through health department staff (as part of routine partner management activities), might be 
more cost-effective and readily implemented in other locations. Much of the essential 
preparatory work of assuring a favorable regulatory and legal environment can also be 
accomplished without programmatic funding. Additional research is needed to evaluate the 
effect of cost to the index patient as a barrier to EPT, as well as to explore methods to 
minimize cost for providing treatment for partners among insured patients. Given the strong 
evidence demonstrating an individual-level benefit for EPT, recent work suggesting that EPT 
may lead to modest reductions in population-level morbidity, and findings demonstrating 
that considerably higher levels of uptake are indeed achievable,4,19 we believe that 
additional efforts are warranted at all levels of the public health and health care systems to 
realize the full potential of EPT in the United States.
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TABLE 1.
Reported Cases of Gonorrhea, Sample Fraction, and Interview Response Rate by SSuN Site, 2010–2012
SSuN Jurisdiction Reported Cases 2010–2012 Sampled Cases and Sample Fraction Interviewed Cases and Response Rate
Baltimore City 7602 1053 13.9% 825 78.3%
California (excluding SF) 80,867 8354 10.3% 3783 45.3%
Colorado 5604 1446 25.8% 602 41.6%
Connecticut 5006 1196 23.9% 507 42.4%
New York City 41,558 4594 11.1% 2103 45.8%
Philadelphia 20,587 4921 23.9% 1977 40.2%
Washington State 8839 1799 20.4% 1191 66.2%
Total 170,063 23,363 13.7% 10,988 47.0%
SF indicates San Francisco.
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TABLE 2.
Point Estimates and AORs for Receipt of EPT Among MSM Diagnosed As Having Gonorrhea by Patient 
Characteristics, SSuN, 2010–2012
EPT Use* 95% CI Adjusted OR 95% CI
Total 2.6% 1.7–3.4 — —
SSuN site
 Baltimore City 13.2% 6.1–20.3 7.29 1.62–32.78
 California (excluding SF) 2.6% 1.2–3.9 1.28 0.45–3.72
 Colorado 2.1% 0.2–3.9 Reference —
 Connecticut 1.4% 0.0–3.4 0.56 0.09–3.52
 New York City 0.08% 0.0–0.2 0.04 0.00–0.35
 Philadelphia 1.9% 1.1–3.9 0.77 0.17–3.55
 Washington State 11.1% 6.6–15.7 6.73 2.38–19.10
Age group, y
 ≤19 1.8% 0.4–3.3 Reference —
 20–24 2.9% 1.6–4.4 1.44 0.57–3.65
 25–29 3.0% 0.6–5.5 1.71 0.54–5.37
 30–39 2.3% 0.9–3.7 1.24 0.46–3.39
 40+ 1.9% 0.5–3.4 0.88 0.30–2.56
Race†
 Black 2.3% 0.8–3.8 0.79 0.25–2.58
 Hispanic 1.9% 0.4–3.4 0.55 0.22–1.36
 White 3.5% 2.0–5.0 Reference —
 Other 2.0% 0.1–3.9 0.47 0.16–1.37
Provider setting
 Hospital (including ED) 2.5% 0.5–4.5 1.72 0.73–4.04
 FP/RH 5.8% 1.7–9.9 2.54 1.03–6.26
 Private/HMO 1.3% 0.5–2.1 0.69 0.31–1.51
 STD clinic 2.6% 1.5–3.6 Reference —
 Other public clinic 1.6% 0.0–3.8 1.65 0.40–6.86
 Other/Unk‡ 4.3% 1.2–7.4 2.21 1.00–4.87
*
Point estimate of proportion of eligible MSM patients reporting receipt of EPT
†
Race/Ethnicity missing for 1.2% of interviewed MSM respondents; “Other” category includes Asian, Native Hawaiian/Other Pacific Islanders, 
and other race.
‡
Provider setting unknown for 6.4% of MSM respondents; “Other” (13.7%) includes HIV care, corrections, military, school-based, and provider 
types not otherwise specified.
SF indicates San Francisco; FP/RH, family planning/reproductive health; HMO, health maintenance organization; Unk, unknown.
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TABLE 3.
Point Estimates and AORs for Receipt of EPT Among Heterosexuals Diagnosed As Having Gonorrhea by 
Patient Characteristics, SSuN, 2010–2012
EPT Use* 95% CI Adjusted OR 95% CI
Total 6.6% 5.5–7.7 — —
SSuN site
 Baltimore City 7.8% 5.2–10.5 0.89 0.49–1.62
 California (excluding SF) 7.9% 5.7–10.1 0.80 0.50–1.29
 Colorado 8.9% 5.2–12.6 Reference —
 Connecticut 1.5% 0.2–2.7 0.13 0.05–0.35
 New York City 0.04% 0.0–1.8 0.08 0.02–0.33
 Philadelphia 1.7% 1.0–2.4 0.16 0.09–0.29
 Washington State 35.5% 30.3–40.7 6.66 4.03–10.99
Sex
 Male 5.6% 3.7–7.4 0.67 0.47–0.95
 Female 7.3% 5.9–8.7 Reference —
Age group, y
 ≤19 4.9% 3.7–6.3 Reference —
 20–24 6.2% 4.3–8.1 1.14 0.72–1.80
 25–29 9.0% 5.6–12.3 1.57 0.98–2.53
 30–39 9.6% 5.1–14.1 1.82 1.03–3.23
 40+ 4.2% 2.3–6.1 0.77 0.45–1.29
Race†
 Black 4.7% 3.5–5.8 1.00 0.63–1.59
 Hispanic 7.2% 4.2–10.2 1.29 0.76–2.17
 White 9.9% 7.1–12.8 Reference —
 Other 12.3% 7.4–17.2 1.46 0.82–2.61
Provider setting
 Hospital (including ED) 3.7% 2.2–5.2 0.48 0.28–0.82
 FP/RH 13.6% 10.5–16.8 1.53 1.00–2.33
 Private/HMO 5.3% 3.2–7.4 0.46 0.28–0.76
 STD clinic 5.7% 4.2–7.3 Reference —
 Other public clinic 9.8% 2.6–17.0 1.48 0.71–3.11
 Other/Unk‡ 6.2% 4.0–8.4 0.59 0.37–0.95
*
Point estimate of proportion of eligible heterosexual patients reporting receipt of EPT.
†
Race/Ethnicity missing for less than 1% of interviewed heterosexual respondents; “Other” category includes Asian, Native Hawaiian/Other Pacific 
Islanders, and other race.
‡
Provider setting unknown for 8.7% of heterosexual respondents; “Other” (7.1%) includes HIV care, corrections, military, school-based, and 
provider types not otherwise specified.
SF indicates San Francisco; FP/RH, family planning/reproductive health; HMO, health maintenance organization; Unk, unknown.
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